MedTrace Logo

Nosocomial Influenza Surveillance of 2022 - 2027 Seasonal Period

NCT05712759 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2025-03-11

No results posted yet for this study

Summary

Hospital-Acquired Influenza (HAI) is closely linked to the intensity of influenza in the community. HAI is associated with significant morbidity, mortality and extra costs due to prolonged hospital stay. The incidence of laboratory confirmed HAI has been reported rarely. The proportion of HAI among influenza cases was 11.38% (95% Confidence Interval: 5.19%-19.55%) in a meta-analysis of 14 studies. In France, a prospective surveillance study of adults with Influenza-Like Illness (ILI) over 11 years, reported that 35.6% of the influenza cases diagnosed at hospital were hospital-acquired.

HAI is transmitted via respiratory droplets and by hand contacts. The spread is facilitated by Health Care Professionals (HCPs), patients and visitors.

Prevention and control of HAI is of upmost importance to preserve patient safety and limit the related economic costs. While vaccination of HCPs has been shown to contribute to the reduction of HAI, less is known on the impact of patient vaccination on the risk of HAI during hospitalization.

The aim of this study is to describe the hospital-acquired influenza in a french university hospital.

Conditions

  • Infection Viral

Interventions

OTHER

Influenza-like illness group

Each patient who present ILI (influenza-like illness) at admission or during hospitalization and who have had a nasopharyngeal swab taken as part of their care for the purpose of diagnosing influenza by Polymerase Chain reaction (PCR) testing. ILI is defined by fever \> 37,8°C or/and cough or sore throat.

Sponsors & Collaborators

  • Hospices Civils de Lyon

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-09
Primary Completion
2025-03-09
Completion
2025-03-09

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05712759 on ClinicalTrials.gov